Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
ZK-EPO
National Institutes of Health
Create Alert
Related topics
Related topics
2 relations
Broader (2)
ZK-Epothilone
sagopilone
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases.
R. Freedman
,
E. Bullitt
,
+8 authors
N. Lin
Clinical breast cancer
2011
Corpus ID: 40138219
UNLABELLED Treatments for women with recurrent brain metastases from breast cancer are limited. In this phase II study,we…
Expand
2010
2010
Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors.
P. Schmid
,
P. Kiewe
,
+7 authors
D. Kuehnhardt
Annals of oncology : official journal of the…
2010
Corpus ID: 35129534
BACKGROUND Sagopilone (ZK-EPO) is a fully synthetic microtubule-stabilizing agent that has demonstrated high antitumor activity…
Expand
Review
2010
Review
2010
Management of Metastatic Breast Cancer: Monotherapy Options for Patients Resistant to Anthracyclines and Taxanes
E. Rivera
American journal of clinical oncology
2010
Corpus ID: 22323943
Resistance to chemotherapeutic agents is a significant obstacle to the effective treatment of metastatic breast cancer (MBC…
Expand
2009
2009
Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas
A. Silvani
,
P. Gaviani
,
+5 authors
A. Salmaggi
Journal of Neuro-Oncology
2009
Corpus ID: 1844551
It has been demonstrated that sagopilone (ZK-EPO) has antitumor activity in human orthotopic glioma models in vitro and in vivo…
Expand
Review
2008
Review
2008
Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate.
U. Klar
,
J. Hoffmann
,
M. Giurescu
Expert opinion on investigational drugs
2008
Corpus ID: 21263208
BACKGROUND Tubulin is among the most established and clinically validated targets in oncology. The taxanes, paclitaxel and…
Expand
Review
2008
Review
2008
Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate
U. Klar
,
J. Hoffmann
,
M. Giurescu
2008
Corpus ID: 71860071
Background: Tubulin is among the most established and clinically validated targets in oncology. The taxanes, paclitaxel and…
Expand
Highly Cited
2008
Highly Cited
2008
Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.
J. Hoffmann
,
I. Vitale
,
+19 authors
G. Kroemer
Cancer research
2008
Corpus ID: 15798594
Sagopilone (ZK-EPO) is the first fully synthetic epothilone undergoing clinical trials for the treatment of human tumors. Here…
Expand
2008
2008
Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC)
J. Graff
,
D. Smith
,
L. Neerukonda
,
M. Alonso
,
G. R. Jones
,
T. Beer
2008
Corpus ID: 74673179
5141 Background: The microtubule stabilizer docetaxel, in combination with prednisone, prolongs life in patients with metastatic…
Expand
2008
2008
Phase I trial of the novel epothilone sagopilone (ZK-EPO) in combination with cisplatin as first-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC)
T. Gauler
,
D. Christoph
,
+7 authors
W. Eberhardt
2008
Corpus ID: 74091956
19081 Background: Sagopilone, a novel epothilone, has shown preclinical activity against SCLC cell lines. A completed Phase I…
Expand
2008
2008
Gateways to clinical trials.
M. Bayes
,
X. Rabasseda
Methods and findings in experimental and clinical…
2008
Corpus ID: 29035991
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE